Kun Li

Kun Li

Auto-generated profile, based on publicly available information

Kun Li

Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
TLTongtong Lin
Tongtong Lin
LHLiang Hu
Liang Hu
FHFan Hu
Fan Hu
KLKun Li
Kun Li
CWChao-Yu Wang
Chao-Yu Wang
WLWen-Tao Liu
Wen-Tao Liu
Oxaliplatin is an antineoplastic agent frequently used in the treatment of gastrointestinal tumors. However, it causes dose-limiting sensorimotor neuropathy, referred to as oxaliplatin-induced peripheral neuropathy (OIPN), for which there is no effective treatment. Here, we report that the elevation of neutrophil extracellular traps (NET) is a pathologic change common to both cancer patients treated with oxaliplatin and a murine model of OIPN. Mechanistically, we found that NETs trigger NLR family pyrin domain containing 3 (NLRP3) inflammasome activation and the subsequent release of IL18 by macrophages, resulting in mechanical hyperalgesia. In NLRP3-deficient mice, the mechanical hyperalgesia characteristic of OIPN in our model was reduced. In addition, in the murine model, treatment with the IL18 decoy receptor IL18BP prevented the development of OIPN. We further showed that eicosapentaenoic acid (EPA) reduced NET formation by suppressing the LPS–TLR4–JNK pathway and thereby abolished NLRP3 inflammasome activation and the subsequent secretion of IL18, which markedly prevented oxaliplatin-induced mechanical hyperalgesia in mice. These results identify a role for NET-triggered NLRP3 activation and IL18 release in the development of OIPN and suggest that utilizing IL18BP and EPA could be effective treatments for OIPN.


4 April 2023
Verified
Other
Open access
TLTongtong Lin
Tongtong Lin
LHLiang Hu
Liang Hu
FHFan Hu
Fan Hu
KLKun Li
Kun Li
CWChao-Yu Wang
Chao-Yu Wang
WLWen-Tao Liu
Wen-Tao Liu
Supplementary Figure from NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy


4 April 2023
Verified
Other
Open access
TLTongtong Lin
Tongtong Lin
LHLiang Hu
Liang Hu
FHFan Hu
Fan Hu
KLKun Li
Kun Li
CWChao-Yu Wang
Chao-Yu Wang
WLWen-Tao Liu
Wen-Tao Liu
Supplementary Figure from NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy